Treatment of Schizophrenia: Past, Present and Future

References

• Cetin M. A Brief History of Psychiatry. In: Ceylan ME, Cetin M. eds. Research and Clinical Practice of Biological Psychiatry, Schizophrenia. 3rd edition. Istanbul: Kure Publishing Group; 2005. p. 1–65. (Turkish)
   Google Scholar
• Cetin M. General information. In: Ceylan ME, Cetin M. eds. Research and Clinical Practice of Biological Psychiatry, Schizophrenia. 3rd edition. Istanbul: Kure Publishing Group; 2005. p. 66–99. (Turkish)
   Google Scholar
• Cetin M. Polypharmacy is a need in psychiatric practice. Klinik Psikofarmakoloji Bulteni-Bulletin of Clinical Psychopharmacology 2014; 24(Suppl 1): S49.
   Google Scholar
• Cetin M. A serious risk: excessive and inappropriate antipsychotic prescribing. Klinik Psikofarmakoloji Bulteni-Bulletin of Clinical Psychopharmacology 2014; 24(1): 1–4. [CrossRef]
   Web of Science ®Google Scholar
• Cetin M, Aricioglu A, Acikel CH, Kilic S. Today's psychopharmacological treatments: results, problems, new perspectives. Klinik Psikofarmakoloji Bulteni-Bulletin of Clinical Psychopharmacology 2012; 22(2): 198–204. [CrossRef]
   Web of Science ®Google Scholar
• Cetin M, Kilic S. How to comprehend the recent meta-analyses conducted on typical and atypical antipsychotics? Klinik Psikofarmakoloji Bulteni-Bulletin of Clinical Psychopharmacology 2009; 19(1): 1–4. (Turkish)
   Google Scholar
• Barlas IO, Cetin M, Erdal ME, Semiz UB, Basoglu C, Ay ME, et al. Lack of association between DRD3 gene polymorphism and response to clozapine in Turkish schizoprenia patients. Am J Med Genet B Neuropsychiatr Genet. 2009; 150B(1): 56–60. [CrossRef]
   Web of Science ®Google Scholar
• Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353(12): 1209–23. [CrossRef]
   PubMed Web of Science ®Google Scholar
• Osser DN, Roudsari MJ, Manschreck T. The psychopharmacology algorithm Project at the Harvard South Shore program: An update on schizophrenia. Harv Rev Psychiatry 2013; 21(1): 18–40. [CrossRef]
   PubMed Web of Science ®Google Scholar
• Brown S, Kim M, Mitchell C, Inskip H. Twenty-five year mortality of a community cohort with schizophrenia. Br J Psychiatry 2010; 196(2): 116–21. [CrossRef]
   PubMed Web of Science ®Google Scholar
• Daumit GL, Pratt LA, Crum RM, Powe NR, Ford DE. Characteristics of primary care visits for individuals with severe mental illness in a national sample. Gen Hosp Psychiatry 2002; 24(6): 391–5. [CrossRef]
   PubMed Web of Science ®Google Scholar
• Meyer JM, Nasrallah HA. Medical Illness and Schizophrenia. Arlington, VA: American Psychiatric Publishing, Inc; 2009.
   Google Scholar
• Nasrallah HA, Meyer JM, Goff DC, McEvoy JP, Davis SM, Stroup TS, et al. Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline. Schizophr Res 2006; 86(1–3): 15–22. [CrossRef]
   PubMed Web of Science ®Google Scholar
• Basoglu C, Oner O, Ates AM, Algul A, Semiz UB, Ebrinc S, et al. Association between symptom improvement and change of body mass index, lipid profile, and leptin, ghrelin, and cholecystokinin levels during 6-week olanzapine treatment in patients with first-episode psychosis. J Clin Psychopharmacol 2010; 30(5): 636–8. [CrossRef]
   Web of Science ®Google Scholar
• Osborn DP, Levy G, Nazareth I, Petersen I, Islam A, King MB. Relative risk of cardiovascular and cancer mortality in people with severe mental illness from the United Kingdom's General Practice Research Database. Arch Gen Psychiatry 2007; 64(2): 242–9. [CrossRef]
   PubMed Web of Science ®Google Scholar
• Osby U, Correia N, Brandt L, Ekbom A, Sparén P. Mortality and causes of death in schizophrenia in Stockholm county, Sweden. Schizophr Res 2000; 45(1–2): 21–8. [CrossRef]
   PubMed Web of Science ®Google Scholar
• Glassman AH, Bigger JT Jr. Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death. Am J Psychiatry 2001; 158(11): 1774–82. [CrossRef]
   PubMed Web of Science ®Google Scholar
• Lin HC, Hsiao FH, Pfeiffer S, Hwang YT, Lee HC. An increased risk of stroke among young schizophrenia patients. Schizophr Res 2008; 101(1–3): 234–41. [CrossRef]
   Web of Science ®Google Scholar
• Copeland LA, Mortensen EM, Zeber JE, Pugh MJ, Restrepo MI, Dalack GW. Pulmonary disease among inpatient decedents: Impact of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31(3): 720–6. [CrossRef]
   Web of Science ®Google Scholar
• Lawrence D, Holman CD, Jablensky AV, Threlfall TJ, Fuller SA. Excess cancer mortality in Western Australian psychiatric patients due to higher case fatality rates. Acta Psychiatr Scand 2000; 101(5): 382–8. [CrossRef]
   Web of Science ®Google Scholar
• Cetin M. A comparative study of atypical antipsychotics on sexual dysfunction. International Journal of Neuropsychopharmacology 2010; 13(Suppl 1): S89.
   Google Scholar
• Hor K, Taylor M. Suicide and schizophrenia: a systematic review of rates and risk factors. J Psychopharmacol 2010; 24(Suppl 4): S81–S90. [CrossRef]
   Web of Science ®Google Scholar
• Meltzer HY. Suicide in schizophrenia, clozapine and adoption of evidence-based medicine. J Clin Psychiatry 2005; 66(4): 530–3. [CrossRef]
   Web of Science ®Google Scholar
• Basoglu C, Cetin M, Oner O, Ebrinc S, Semiz UB, Kandilcioglu H, et al. Comparison of right thalamus and temporal cortex metabolite levels of drug-naive firstepisode psychotic and chronic schizophrenia in patients. Turk Psikiyatri Derg 2006; 17(2): 85–91.
   Web of Science ®Google Scholar
• Landolt K, Rössler W, Burns T, Ajdacic-Gross V, Galderisi S, Libiger J, et al; EUFEST Study Group. Unmet needs in patients with first-episode schizophrenia: a longitudinal perspective. Psychol Med 2012; 42(7): 1461–13. [CrossRef]
   Web of Science ®Google Scholar
• Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 2013; 382(9896): 951–62. [CrossRef]
   PubMed Web of Science ®Google Scholar
• Leucht C, Heres S, Kane JM, Kissling W, Davis JM, Leucht S. Oral versus depot antipsychotic drugs for schizophrenia a critical systematic review and meta-analysis of randomised long-term trials. Schizophr Res 2011; 127(1–3): 83–92. [CrossRef]
   PubMed Web of Science ®Google Scholar
• Rosenheck RA, Krystal JH, Lew R, Barnett PG, Fiore L, Valley D, et al. Long-acting risperidone and oral antipsychotics in unstable schizophrenia. N Engl J Med 2011; 364(9): 842–51. [CrossRef]
   PubMed Web of Science ®Google Scholar
• Kane JM, Detke HC, Naber D, Sethuraman G, Lin DY, Bergstrom RF, et al. Olanzapine long-acting injection: a 24-week, randomized, double-blind trial of maintenance treatment in patients with schizophrenia. Am J Psychiatry 2010; 167(2): 181–9. [CrossRef]
   PubMed Web of Science ®Google Scholar
• Macfadden W, Ma YW, Thomas Haskins J, Bossie CA, Alphs L. A prospective study comparing the long-term effectiveness of injectable risperidone long-acting therapy and oral aripiprazole in patients with schizophrenia. Psychiatry 2010; 7: (11)23–31.
   Google Scholar
• Kishimoto T, Robenzadeh A, Leucht C, Leucht S, Watanabe K, Mimura M, et al. Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials. Schizophr Bull 2014; 40(1): 192–213. [CrossRef]
   PubMed Web of Science ®Google Scholar
• Leucht S, Tardy M, Komossa K, Heres S, Kissling W, Salanti G, et al. Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. Lancet 2012; 379(9831): 2063–71. [CrossRef]
   PubMed Web of Science ®Google Scholar
• Dhami K, MacKay M, Maia-de-Oliveira JP, Hallak J, Todd K, Baker G, et al. Novel targets for development of drugs for treating schizophrenia: focus on glycine, D-serine and nitric oxide. Klinik Psikofarmakoloji Bulteni-Bulletin of Clinical Psychopharmacology 2013; 23(2): 129–37. [CrossRef]
   Web of Science ®Google Scholar
• Cetin M, Aricioglu F. Sights for sore eyes and disappointments in psychopharmacology. Klinik Psikofarmakoloji Bulteni-Bulletin of Clinical Psychopharmacology 2014; 24(2): 111–4. [CrossRef]
   Web of Science ®Google Scholar
• Aricioglu F, Cetin M. Personalized drug therapy in psychiatry: maybe a little old or a little new, but the treatment of future. Klinik Psikofarmakoloji Bulteni-Bulletin of Clinical Psychopharmacology 2010; 20(4): 269–71. (Turkish)
   Google Scholar